Page last updated: 2024-12-06

3-carbethoxypsoralen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

3-Carbethoxypsoralen (3-CP) is a synthetic psoralen derivative used in photochemotherapy for treating psoriasis and other skin conditions. It has a similar structure to psoralen but contains an additional carbethoxy group at the 3-position. This modification enhances its photoreactivity, allowing it to bind to DNA more effectively when exposed to ultraviolet A (UVA) light. 3-CP is administered orally or topically and, upon exposure to UVA light, forms a covalent adduct with DNA, inhibiting cell proliferation and reducing inflammation. Its effectiveness in treating psoriasis is attributed to its ability to suppress the immune response and regulate keratinocyte differentiation. 3-CP is studied extensively due to its clinical application in dermatology and its potential in treating other conditions, such as vitiligo and cutaneous T-cell lymphoma. It has been shown to have anti-inflammatory, immunomodulatory, and antiproliferative effects. However, 3-CP can also cause side effects, including phototoxicity, skin pigmentation changes, and an increased risk of skin cancer. Research continues to explore its potential benefits and risks, including the development of safer and more effective psoralen derivatives.'

Cross-References

ID SourceID
PubMed CID62739
CHEBI ID50100
SCHEMBL ID498755
MeSH IDM0067566

Synonyms (33)

Synonym
ethyl 7-oxo-7h-furo[3,2-g]chromene-6-carboxylate
CHEBI:50100
3-(ethoxycarbonyl)psoralen
20073-24-9
3-carbethoxypsoralen
3-cp
brn 0278285
3-ethoxycarbonylpsoralen
einecs 243-498-7
7h-furo(3,2-g)(1)benzopyran-6-carboxylic acid, 7-oxo-, ethyl ester
ethyl 7-oxo-7h-furo(3,2-g)(1)benzopyran-6-carboxylate
7-oxo-7h-furo(3,2-g)(1)benzopyran-6-carboxylic acid ethyl ester
((6-hydroxy-5-benzofuranyl)methylene)malonic acid, gamma-lactone, ethyl ester
ethyl 3-psoralencarboxylate
3-cps
ethyl 7-oxofuro[3,2-g]chromene-6-carboxylate
C19357
unii-bb04z808hm
5-19-08-00079 (beilstein handbook reference)
bb04z808hm ,
carbethoxypsoralen, 3-
3-carbethoxypsoralen [iarc]
SCHEMBL498755
CFQAMEDTKHNQTP-UHFFFAOYSA-N
DTXSID2074875
ethyl 7-oxo-7h-furo[3,2-g][1]benzopyran-6-carboxylate
AKOS030599869
HY-U00265
CS-7194
Q27121904
3-carbethoxypsoralen; 3-ethoxycarbonylpsoralen
ethyl7-oxo-7h-furo[3,2-g]chromene-6-carboxylate
PD099749

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These studies show that the psoralens with two potential DNA-binding sites (8-MOP and 5-MOP) were more toxic than psoralens with only one photoreactive site (5-MIP and 3-CEP)."( Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse.
Davies, RE; Dunnick, JK; Forbes, PD; Iverson, WO, 1987
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (73.91)18.7374
1990's10 (21.74)18.2507
2000's1 (2.17)29.6817
2010's1 (2.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.24 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.88%)6.00%
Case Studies1 (1.96%)4.05%
Observational0 (0.00%)0.25%
Other47 (92.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]